Molecular alterations and clinical prognostic factors in resectable non-small cell lung cancer

Abstract Background EGFR inhibitor and immunotherapy have been approved for adjuvant treatment in resectable non-small cell lung cancer (NSCLC). Limited reports of molecular and clinical characteristics as prognostic factors in NSCLC have been published. Methods Medical records of patients with resectable NSCLC stage I–III diagnosed during 2015–2020 were reviewed. Real time-PCR (RT-PCR) was performed for EGFR mutations (EGFRm). Immunohistochemistry staining was conducted for ALK and PD-L1 expression. Categorical variables were compared using chi-square test and Fisher’s exact test. Survival analysis was done by cox-regression method. Results Total 441 patients were included. The prevalence of EGFRm, ALK fusion, and PD-L1 expression were 57.8%, 1.9%, and 20.5% (SP263), respectively. The most common EGFRm were Del19 (43%) and L858R (41%). There was no significant difference of recurrence free survival (RFS) by EGFRm status whereas patients with PD-L1 expression (PD-L1 positive patients) had lower RFS compared to without PD-L1 expression (PD-L1 negative patients) (HR = 1.75, P = 0.036). Patients with both EGFRm and PD-L1 expression had worse RFS compared with EGFRm and PD-L1 negative patients (HR = 3.38, P = 0.001). Multivariable analysis showed higher CEA at cut-off 3.8 ng/ml, pT4, pN2, pStage II, and margin were significant poor prognostic factors for RFS in the overall population, which was similar to EGFRm population (exception of pT and pStage). Only pStage was a significant poor prognostic factor for PD-L1 positive patients. The predictive score for predicting of recurrence were 6 for all population (63% sensitivity and 86% specificity) and 5 for EGFRm population (62% sensitivity and 93% specificity). Conclusion The prevalence and types of EGFRm were similar between early stage and advanced stage NSCLC. While lower prevalence of PD-L1 expression was found in early stage disease. Patients with both EGFRm and PD-L1 expression had poorer outcome. Thus PD-L1 expression would be one of the prognostic factor in EGFRm patients. Validation of the predictive score should be performed in a larger cohort

Growing and laying performance of Japanese quail fed diet supplemented with different concentrations of acetic acid

<p>In order to evaluate the effect of acetic acid on growing and laying performance of Japanese Quail (JQ), 180 15-day-old JQ were divided into 4 groups. During the growing (15-42 days of age) and laying (43-84 days of age) periods, the groups fed the same basal diets supplemented with 0, 1.5, 3 and 6% of acetic acid. Each diet was fed to five replicates of 9 JQ (3 males:6 females) during the growing period. During the laying period, 128 birds were housed in 32 cages (4 birds per cage, 1 male and 3 females, 8 replicates per treatment). Birds were housed in wire cages (46L×43W×20H cm) in an open room. Acetic acid supplementation at 3% in the diets significantly increased the growth and laying rate and the Haugh unit score. The liver percentage significantly decreased with acetic acid at 6%. Acetic acid at 3% significantly increased hemoglobin concentrations at 6 weeks of age and increased weight of day old chicks hatched.<strong> </strong>Acetic acid affected the immune system as manifested by an excess of cellular reactions in the intestine as well as lymphoid hyperplasia in the spleen tissue. Degenerative changes in the covering epithelium of the intestinal villi were noted at the 6% concentration of acetic acid. Hepatocyte vacuolation and fatty changes were also observed at this concentration of treatment. In conclusion, 3% acetic acid may be used as a feed supplement for JQ during the growing and laying period to improve the productive performance.</p><br /

Additional file 1 of Molecular alterations and clinical prognostic factors in resectable non-small cell lung cancer

Additional file 1: Supplement figure 1. ROC curve of predictive score of overall population. Supplement figure 2. ROC curve of predictive score of EGFRm cohort